PL3421493T3 - Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania - Google Patents

Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania

Info

Publication number: PL3421493T3
Authority: PL; Poland
Prior art keywords: progastrin; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2009-10-16

Application number

PL18185172.6T

Other languages

English (en)

Inventor

Julie Pannequin

Laure Boudier

Dominique Joubert

Frédéric HOLLANDE

Original Assignee

Progastrine Et Cancers S.À R.L.

Centre National De La Recherche Scientifique (Cnrs)

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-16

Filing date

2010-10-15

Publication date

2024-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3421493(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-15 Application filed by Progastrine Et Cancers S.À R.L., Centre National De La Recherche Scientifique (Cnrs), Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Progastrine Et Cancers S.À R.L.

2024-04-29 Publication of PL3421493T3 publication Critical patent/PL3421493T3/pl

Links

101800000285 Big gastrin Proteins 0.000 title 1
RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL18185172.6T 2009-10-16 2010-10-15 Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania PL3421493T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25262509P	2009-10-16	2009-10-16

Publications (1)

Publication Number	Publication Date
PL3421493T3 true PL3421493T3 (pl)	2024-04-29

Family

ID=43086711

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10768878T PL2488551T3 (pl)	2009-10-16	2010-10-15	Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
PL18185172.6T PL3421493T3 (pl)	2009-10-16	2010-10-15	Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL10768878T PL2488551T3 (pl)	2009-10-16	2010-10-15	Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania

Country Status (42)

Country	Link
US (7)	US9611320B2 (pl)
EP (2)	EP2488551B1 (pl)
JP (3)	JP5985987B2 (pl)
KR (2)	KR101640520B1 (pl)
CN (2)	CN102791735B (pl)
AP (1)	AP2012006262A0 (pl)
AR (1)	AR078659A1 (pl)
AU (1)	AU2010306119A1 (pl)
BR (1)	BR112012008818B1 (pl)
CA (1)	CA2777691C (pl)
CL (1)	CL2012000914A1 (pl)
CR (1)	CR20120184A (pl)
CU (1)	CU24196B1 (pl)
CY (1)	CY1120913T1 (pl)
DK (1)	DK2488551T3 (pl)
EA (2)	EA201791876A1 (pl)
EC (1)	ECSP12011796A (pl)
ES (2)	ES2690943T3 (pl)
GE (1)	GEP201706604B (pl)
GT (1)	GT201200114A (pl)
HN (1)	HN2012000708A (pl)
HR (1)	HRP20181645T1 (pl)
IL (2)	IL219019B (pl)
IN (1)	IN2012DN03348A (pl)
LT (1)	LT2488551T (pl)
MA (1)	MA33747B1 (pl)
MX (1)	MX351635B (pl)
NI (1)	NI201200054A (pl)
NZ (2)	NZ701709A (pl)
PE (1)	PE20121649A1 (pl)
PH (1)	PH12012500711B1 (pl)
PL (2)	PL2488551T3 (pl)
PT (1)	PT2488551T (pl)
RS (1)	RS57966B1 (pl)
SG (1)	SG10201704933PA (pl)
SI (1)	SI2488551T1 (pl)
SM (1)	SMT201800628T1 (pl)
TN (1)	TN2012000159A1 (pl)
TW (1)	TWI537002B (pl)
UA (1)	UA106771C2 (pl)
WO (1)	WO2011045080A2 (pl)
ZA (1)	ZA201202642B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008076454A1 (en)	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) *	2007-12-14	2012-03-20	The Procter & Gamble Company	Method and apparatus for orienting articles
PL2488551T3 (pl) *	2009-10-16	2019-01-31	Progastrine Et Cancers S.À R.L.	Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
US8900588B2 (en) *	2010-01-08	2014-12-02	Les Laboratories Servier	Methods for treating breast cancer
US8900817B2 (en)	2010-01-08	2014-12-02	Les Laboratories Servier	Progastrin and liver pathologies
CA2793647C (en) *	2010-03-24	2020-09-01	Biorealites	Prophylaxis of colorectal and gastrointestinal cancer
BR112013002012A2 (pt) *	2010-07-26	2019-08-27	Centre Nat Rech Scient	métodos e composições para terapia de câncer de fígado
US8785603B2 (en)	2011-05-20	2014-07-22	Siemens Healthcare Diagnostics Inc.	Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
WO2012164035A1 (en)	2011-06-01	2012-12-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for predicting the risk of developing a colonic neoplasia
JP6450381B2 (ja)	2013-07-05	2019-01-09	ユニバーシティオブワシントンスルーイッツセンターフォーコマーシャリゼーション	がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
EP3797793A1 (en)	2014-04-18	2021-03-31	The Research Foundation of the State University of New York at Buffalo	Humanized anti-tf-antigen antibodies
US10023651B2 (en)	2014-04-18	2018-07-17	The Research Foundation For The State University Of New York	Humanized anti-TF-antigen antibodies
WO2016066671A1 (en)	2014-10-29	2016-05-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating resistant cancers using progastrin inhibitors
AU2016324021A1 (en) *	2015-09-15	2018-04-12	The Scripps Research Institute	Antibodies for generating anti-inflammatory macrophage and related uses
MA43550A (fr) *	2015-12-31	2018-11-07	Syncerus S A R L	Compositions et procédés d'évaluation du risque d'apparition d'un cancer
US11760808B2 (en) *	2015-12-31	2023-09-19	Progastrine Et Cancers S.À R.L.	Compositions and methods for detecting and treating ovarian cancer
JP6909795B2 (ja) *	2015-12-31	2021-07-28	プロガストリン、エ、カンセル、エス、アーエル、エルＰｒｏｇａｓｔｒｉｎｅＥｔＣａｎｃｅｒｓＳ．ＡＲ．Ｌ．	胃癌の検出および治療のための組成物および方法
BR112019020224A2 (pt) *	2017-03-30	2020-05-12	Progastrine Et Cancers S.À R.L.	Composições e métodos para o tratamento do câncer de pulmão
ES2904939T3 (es) *	2017-03-30	2022-04-06	Progastrine Et Cancers S A R L	Composiciones y métodos para detectar y tratar el cáncer de próstata utilizando una molécula de unión a progastrina
PL3720879T3 (pl) *	2017-12-05	2022-09-12	Progastrine Et Cancers S.À R.L.	Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu
WO2019110845A1 (en)	2017-12-08	2019-06-13	Ecs-Biotracker Sàrl	Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en)	2018-01-26	2019-08-01	Ecs-Progastrin Sa	Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
KR102699073B1 (ko) *	2018-02-27	2024-08-26	이씨에스-프로가스트린 에스에이	면역치료요법용 생체표지자로서 프로가스트린
TWI793238B (zh) *	2018-12-27	2023-02-21	偉喬生醫股份有限公司	體外檢測生物樣品之胃源性蛋白的方法及套組
WO2021066751A1 (en) *	2019-10-02	2021-04-08	Aslan Pharmaceuticals Pte. Ltd.	Antigen specific binding domains and antibody molecules
CN112062846A (zh) *	2020-04-27	2020-12-11	杭州博茵生物技术有限公司	一种g-17单克隆抗体及其应用
CN115785273B (zh) *	2021-09-10	2023-10-31	东莞市朋志生物科技有限公司	一种抗胃蛋白酶原i的抗体及其应用
CN115724949A (zh) *	2022-12-12	2023-03-03	郑州伊美诺生物技术有限公司	一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) *	2022-12-30	2023-05-23	南京岚煜生物科技有限公司	胃泌素17的单克隆抗体及其细胞株的制备方法和应用
US20250059271A1 (en) *	2023-08-16	2025-02-20	Barrelman Biosciences Llc	Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN117567611B (zh) *	2023-11-22	2024-05-14	艾维可生物科技有限公司	抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DE69133566T2 (de)	1990-01-12	2007-12-06	Amgen Fremont Inc.	Bildung von xenogenen Antikörpern
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US8158128B2 (en) *	2004-09-22	2012-04-17	Cancer Advances, Inc.	Monoclonal antibodies to progastrin
PL2040753T3 (pl) *	2006-05-22	2019-09-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibitory progastryny w leczeniu raka okrężnicy
WO2008076454A1 (en)	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US20110318380A1 (en) *	2008-10-01	2011-12-29	Dako Denmark A/S	MHC Multimers in Cancer Vaccines and Immune Monitoring
PL2488551T3 (pl) *	2009-10-16	2019-01-31	Progastrine Et Cancers S.À R.L.	Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
CA2793647C (en) *	2010-03-24	2020-09-01	Biorealites	Prophylaxis of colorectal and gastrointestinal cancer
BR112013002012A2 (pt) *	2010-07-26	2019-08-27	Centre Nat Rech Scient	métodos e composições para terapia de câncer de fígado

2010
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 PH PH1/2012/500711A patent/PH12012500711B1/en unknown
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 SM SM20180628T patent/SMT201800628T1/it unknown
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/en not_active Ceased
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/en active Active
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/en active Active
- 2010-10-15 CA CA2777691A patent/CA2777691C/en active Active
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active Active
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 BR BR112012008818-1A patent/BR112012008818B1/pt active IP Right Grant
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko not_active Ceased
- 2010-10-15 PL PL18185172.6T patent/PL3421493T3/pl unknown
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 HR HRP20181645TT patent/HRP20181645T1/hr unknown
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 ES ES18185172T patent/ES2973217T3/es active Active
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
2017
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
2018
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending

Also Published As

Publication number	Publication date
CU24196B1 (es)	2016-09-30
PH12012500711B1 (en)	2019-04-24
IL219019A0 (en)	2012-06-28
JP2017212992A (ja)	2017-12-07
AU2010306119A1 (en)	2012-05-03
EP2488551A2 (en)	2012-08-22
TN2012000159A1 (en)	2013-12-12
SI2488551T1 (sl)	2019-01-31
US10385126B2 (en)	2019-08-20
TW201119675A (en)	2011-06-16
AR078659A1 (es)	2011-11-23
CN102791735B (zh)	2016-05-18
MX2012004400A (es)	2012-06-27
JP2013507138A (ja)	2013-03-04
KR20150082672A (ko)	2015-07-15
CN104628857A (zh)	2015-05-20
PH12012500711A1 (en)	2012-11-12
CA2777691C (en)	2018-02-27
US20170174761A1 (en)	2017-06-22
KR20120091221A (ko)	2012-08-17
RS57966B1 (sr)	2019-01-31
US20170306012A1 (en)	2017-10-26
US20170306011A1 (en)	2017-10-26
NZ701709A (en)	2016-06-24
ECSP12011796A (es)	2012-06-29
ES2973217T3 (es)	2024-06-19
BR112012008818A2 (pt)	2018-05-22
ZA201202642B (en)	2013-06-26
US20180022802A1 (en)	2018-01-25
US9611320B2 (en)	2017-04-04
JP2015145380A (ja)	2015-08-13
CY1120913T1 (el)	2019-12-11
IL219019B (en)	2019-05-30
CN102791735A (zh)	2012-11-21
MX351635B (es)	2017-10-23
AP2012006262A0 (en)	2012-06-30
IN2012DN03348A (pl)	2015-10-23
US11299542B2 (en)	2022-04-12
WO2011045080A2 (en)	2011-04-21
UA106771C2 (uk)	2014-10-10
EP3421493C0 (en)	2024-01-17
HN2012000708A (es)	2015-06-22
GEP201706604B (en)	2017-01-25
IL254004A0 (en)	2017-10-31
SG10201704933PA (en)	2017-07-28
US10385125B2 (en)	2019-08-20
US20200002413A1 (en)	2020-01-02
PT2488551T (pt)	2018-10-31
LT2488551T (lt)	2018-10-25
EP2488551B1 (en)	2018-07-25
ES2690943T3 (es)	2018-11-23
US20110117086A1 (en)	2011-05-19
JP6272793B2 (ja)	2018-01-31
GT201200114A (es)	2014-08-11
SMT201800628T1 (it)	2019-01-11
CR20120184A (es)	2012-08-20
CL2012000914A1 (es)	2012-09-14
JP5985987B2 (ja)	2016-09-06
BR112012008818B1 (pt)	2021-10-19
EA029271B1 (ru)	2018-03-30
CA2777691A1 (en)	2011-04-21
NI201200054A (es)	2012-08-20
NZ599971A (en)	2014-12-24
US20220195035A1 (en)	2022-06-23
EP3421493A1 (en)	2019-01-02
IL254004B2 (en)	2023-06-01
MA33747B1 (fr)	2012-11-01
US10377821B2 (en)	2019-08-13
EA201791876A1 (ru)	2018-01-31
HK1178183A1 (zh)	2013-09-06
EA201200597A1 (ru)	2012-12-28
US10385124B2 (en)	2019-08-20
TWI537002B (zh)	2016-06-11
PL2488551T3 (pl)	2019-01-31
HRP20181645T1 (hr)	2018-12-14
WO2011045080A3 (en)	2011-07-07
PE20121649A1 (es)	2012-12-08
DK2488551T3 (en)	2018-10-08
KR101640520B1 (ko)	2016-07-19
EP3421493B1 (en)	2024-01-17
CU20120060A7 (es)	2013-04-19

Publication	Publication Date	Title
IL254004A0 (en)	2017-10-31	Monoclonal antibodies to progesterone and their use
IL215696A0 (en)	2012-01-31	Antibodies specific to cadherin-17
ZA201200732B (en)	2013-07-31	Fully human antibodies to btla
IL218724A0 (en)	2012-06-28	Endoglin antibodies
IL214996A0 (en)	2011-11-30	Anti-bcma antibodies
GB0920127D0 (en)	2009-12-30	Antibodies
GB0909906D0 (en)	2009-07-22	Antibodies
ZA201202227B (en)	2014-11-26	Monoclonal antibodies
IL217225A0 (en)	2012-02-29	Humanised antibodies to toll - like receptor 2 and uses thereof
ZA201105918B (en)	2012-10-31	Fully human antibodies specific to cadm1
IL217919A0 (en)	2012-03-29	Humanized anti-cdcp1 antibodies
EP2427496A4 (en)	2013-05-15	ANTI-VEGF-D ANTIBODIES
EP2542258A4 (en)	2013-08-21	MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
GB0920324D0 (en)	2010-01-06	Antibodies
EP2542262A4 (en)	2014-02-26	MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20
EP2499256A4 (en)	2013-09-11	ANTI-C-MPL ANTIBODIES
GB0908945D0 (en)	2009-07-01	Antibodies